Alpha Tau Medical Ltd Cl A (DRTS)

$7.30 +0.34 (4.89%)
Market Cap 588.65M
Revenue (ttm) 0.00
Net Income (ttm) -31.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.08
Volume 294,800
Avg Vol 332,142
Day's Range N/A - N/A
Shares Out 84.82M
Stochastic %K 41%
Beta 1.04
Analysts Sell
Price Target $8.67

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 577 4115
Address:
Kiryat HaMada St. 5, Jerusalem, Israel
Ehri
Ehri Feb. 3 at 8:52 PM
$DRTS I don't see why the bet on this (better) physics (AlphaDart) should fail now. Do you?
1 · Reply
Newport_menthol_Iover
Newport_menthol_Iover Feb. 3 at 8:30 PM
$DRTS smells like MONEY
1 · Reply
JohnStocksNY
JohnStocksNY Feb. 3 at 8:29 PM
$DRTS C’mon let’s finish strong!
0 · Reply
OnlyGB
OnlyGB Feb. 3 at 4:21 PM
$DRTS is moving up. Here. We. Go!!!!!!
1 · Reply
Jessypenny
Jessypenny Feb. 3 at 4:06 PM
$DRTS 🔥🔥🔥
0 · Reply
JohnStocksNY
JohnStocksNY Feb. 3 at 2:52 PM
$DRTS 7 might look like a step back, but just like #77 a step back means something big is about to drop
1 · Reply
JohnStocksNY
JohnStocksNY Feb. 3 at 1:12 PM
$DRTS Keeps hiring! Growth upon growth!
0 · Reply
StockOrTwist
StockOrTwist Feb. 3 at 12:46 PM
$DRTS https://www.youtube.com/watch?v=QJ-JSwozmbk&list=PLG-rFJE9CyVVwaGfeaM4aC1Sg1pegeEeQ&index=17&pp=iAQBsAgC
1 · Reply
psw_psw
psw_psw Feb. 3 at 12:31 PM
$DRTS & AKTIS (AKTS)
1 · Reply
Jessypenny
Jessypenny Feb. 3 at 10:56 AM
$DRTS isn't a "bet" on a single drug—it's a bet on a new law of physics in oncology. 10+ tumor types tested, 0% resistance found. Unlike chemo, Alpha DaRT doesn't care about mutations or low oxygen. It just destroys. With the Japan PMDA decision looming, the market is finally waking up to the "Universal Killer."
1 · Reply
Latest News on DRTS
Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Feb 3, 2026, 12:37 PM EST - 6 hours ago

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Jan 29, 2026, 9:00 AM EST - 5 days ago

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026

Jan 23, 2026, 3:34 AM EST - 11 days ago

Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Jan 6, 2026, 9:00 AM EST - 4 weeks ago

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Jan 5, 2026, 9:00 AM EST - 4 weeks ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Dec 9, 2025, 9:00 AM EST - 2 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 4:05 PM EST - 2 months ago

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Nov 11, 2025, 8:30 AM EST - 3 months ago

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 21, 2025, 8:30 AM EDT - 3 months ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Oct 17, 2025, 10:04 AM EDT - 3 months ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

Oct 16, 2025, 11:55 AM EDT - 3 months ago

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Sep 2, 2025, 8:30 AM EDT - 5 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Alpha Tau to Participate in Five September Investor Conferences

Aug 27, 2025, 8:30 AM EDT - 5 months ago

Alpha Tau to Participate in Five September Investor Conferences

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 4:02 PM EDT - 6 months ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Jul 25, 2025, 9:04 AM EDT - 6 months ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:01 PM EDT - 9 months ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

May 12, 2025, 4:01 PM EDT - 9 months ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

Alpha Tau to Participate in May Investor Conferences

May 6, 2025, 8:30 AM EDT - 9 months ago

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr 28, 2025, 9:00 AM EDT - 10 months ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Apr 28, 2025, 9:00 AM EDT - 10 months ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Apr 2, 2025, 8:30 AM EDT - 10 months ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:02 PM EDT - 11 months ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Feb 24, 2025, 8:30 AM EST - 1 year ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Jan 27, 2025, 9:00 AM EST - 1 year ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 18, 2024, 8:30 AM EST - 1 year ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 17, 2024, 9:00 AM EST - 1 year ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Dec 6, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:02 PM EDT - 1 year ago

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Alpha Tau to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:45 AM EDT - 1 year ago

Alpha Tau to Present at the Jefferies Global Healthcare Conference

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 20, 2024, 4:01 PM EDT - 1 year ago

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

May 13, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

May 6, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Mar 25, 2024, 8:50 AM EDT - 2 years ago

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:01 PM EST - 2 years ago

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Feb 26, 2024, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 9:15 AM EST - 2 years ago

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Sidoti Small-Cap Conference

Nov 29, 2023, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Sidoti Small-Cap Conference

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Nov 28, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Nov 20, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 16, 2023, 4:30 PM EST - 2 years ago

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

Nov 13, 2023, 8:00 AM EST - 2 years ago

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

Oct 30, 2023, 8:30 AM EDT - 2 years ago

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

Ehri
Ehri Feb. 3 at 8:52 PM
$DRTS I don't see why the bet on this (better) physics (AlphaDart) should fail now. Do you?
1 · Reply
Newport_menthol_Iover
Newport_menthol_Iover Feb. 3 at 8:30 PM
$DRTS smells like MONEY
1 · Reply
JohnStocksNY
JohnStocksNY Feb. 3 at 8:29 PM
$DRTS C’mon let’s finish strong!
0 · Reply
OnlyGB
OnlyGB Feb. 3 at 4:21 PM
$DRTS is moving up. Here. We. Go!!!!!!
1 · Reply
Jessypenny
Jessypenny Feb. 3 at 4:06 PM
$DRTS 🔥🔥🔥
0 · Reply
JohnStocksNY
JohnStocksNY Feb. 3 at 2:52 PM
$DRTS 7 might look like a step back, but just like #77 a step back means something big is about to drop
1 · Reply
JohnStocksNY
JohnStocksNY Feb. 3 at 1:12 PM
$DRTS Keeps hiring! Growth upon growth!
0 · Reply
StockOrTwist
StockOrTwist Feb. 3 at 12:46 PM
$DRTS https://www.youtube.com/watch?v=QJ-JSwozmbk&list=PLG-rFJE9CyVVwaGfeaM4aC1Sg1pegeEeQ&index=17&pp=iAQBsAgC
1 · Reply
psw_psw
psw_psw Feb. 3 at 12:31 PM
$DRTS & AKTIS (AKTS)
1 · Reply
Jessypenny
Jessypenny Feb. 3 at 10:56 AM
$DRTS isn't a "bet" on a single drug—it's a bet on a new law of physics in oncology. 10+ tumor types tested, 0% resistance found. Unlike chemo, Alpha DaRT doesn't care about mutations or low oxygen. It just destroys. With the Japan PMDA decision looming, the market is finally waking up to the "Universal Killer."
1 · Reply
Herbgator
Herbgator Feb. 2 at 10:18 PM
$DRTS They just closed out candidates today on LinkedIn for a translational research and immunology specialist in Jerusalem at 26 candidates. IMHO, this hire seems to be a necessary step to evaluate the abscopal effect of localized radiation triggering systemic anti-tumor immunity, leading to regression of distant, non-irradiated metastases, which seemed to be an unexpected event which they talked about at the JP Morgan conference. If this is proven to be substantial in their trials, buckle your seatbelts. IMHO
1 · Reply
JohnStocksNY
JohnStocksNY Feb. 2 at 6:18 PM
$DRTS Featured in Florida Weekly https://www.floridaweekly.com/articles/fw-healthy-living/less-invasive-skin-cancer-treatments/
1 · Reply
SlimyMango
SlimyMango Feb. 2 at 5:51 PM
$DRTS Up to 1k shares in the Roth now :)
1 · Reply
Jessypenny
Jessypenny Feb. 2 at 3:39 PM
$DRTS from TradingView 🔥
1 · Reply
SerraInvest
SerraInvest Feb. 2 at 3:37 PM
$DRTS Watch for volume to confirm breakout
1 · Reply
StockOrTwist
StockOrTwist Feb. 2 at 2:12 PM
$DRTS https://www.youtube.com/watch?v=QJ-JSwozmbk&list=PLG-rFJE9CyVVwaGfeaM4aC1Sg1pegeEeQ&index=14&pp=iAQBsAgC
0 · Reply
CEOofstocks
CEOofstocks Feb. 2 at 1:14 PM
$DRTS after spending some time doing some DD this weekend, this appears to me to have high potential on ticking all of the boxes in my bio, that I look for before investing heavily. While I am looking at this post SLS, I believe I have time. What I really like? - strong management - financial runway and efficiency - high unmet need targeted - massive potential TAM - regular FDA engagement - global reach The biggest risk to me is, the assets are not de-risked as much as I'd like but that doesn't mean you can't start building a position within a careful risk tolerance. Seems some big catalysts are ahead, but I think there is some time here which aligns well for me.
1 · Reply
JohnStocksNY
JohnStocksNY Feb. 2 at 1:00 PM
$DRTS Don’t let em get all these cheap prices
2 · Reply
Jordan3333
Jordan3333 Feb. 2 at 12:43 PM
$DRTS a huge sell off in the small caps at the end of last week, cleaning out the sellers and setting us up for a run
2 · Reply
Itay24
Itay24 Feb. 2 at 12:34 PM
$DRTS The past month has been an absolute heater for $DRTS! If you're looking for a "Green Monday" start, the technical setup is screaming accumulation before the next clinical leg up
1 · Reply
JKtech
JKtech Feb. 2 at 12:00 PM
$DRTS While the broader market is distracted by macro volatility, Alpha Tau is checking every box on its "commercial launch" checklist.
1 · Reply
kareem1988
kareem1988 Feb. 2 at 10:51 AM
$VNDA $DRTS $BMRN $AXSM Put these on your watch list! February is catalyst month. Forget the macro noise—these tickers have massive independent news coming: $DRTS : Japan PMDA decision watch is at high alert. Any day now could be the first commercial approval outside Israel. $VNDA : Huge PDUFA date on Feb 21. FDA decides on Bysanti for Bipolar I/Schizophrenia. Make or break. $BMRN : Earnings on Feb 18. Look for the Voxzogo expansion roadmap and new Phase 3 data. $AXSM : Earnings on Feb 23. Crucial update on Auvelity’s growth and the Alzheimer’s agitation timeline. Clinicals > Macro. Staying focused.
0 · Reply